CompletedPhase 3

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

United States151 participantsStarted 2024-04-02

Plain-language summary

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.

Age range12 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Proportion of Full-dose Self-administered Rocatinlimab Injections Among Total Attempted Injections up to Week 16

Timeframe: Up to Week 16

NCT IDNCT06224192

SponsorAmgen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-04-11